Insulin aspart (Fiasp)

Peptide

Also known as NN1218

Approvedregulatory verdict

Evidence outlook

Approved: Type 2 Diabetes, Type 1 Diabetes

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also approved (1)
EU
  • Diabetes mellitus (Fiasp, fast-acting insulin aspart, Novo Nordisk A/S)
Product first approved 2017EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (12)
Type 1 Diabetes
NCT03977727 · Texas Diabetes & Endocrinology, P.A.
2019-06-11 – 2020-04-20 · Type 1 Diabetes Mellitus
What this study did
NCT02500706 · Novo Nordisk A/S
2016-05-04 – 2017-08-16 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01999322 · Novo Nordisk A/S
2013-11-19 – 2014-05-14 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT04460326 · Boston Medical Center
2020-12-07 – 2023-05-27 · Type 2 Diabetes Treated With Insulin
What this study did
NCT04588259 · Novo Nordisk A/S
2020-10-09 – 2022-08-05 · Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
What this study did
NCT03268005 · Novo Nordisk A/S
2017-09-19 – 2019-01-29 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT03770767 · Copenhagen University Hospital, Rigshospitalet
2019-11-11 – 2023-03-23 · Diabetes Mellitus, Pregnancy Complications
What this study did
Phase 2/3 (1)
Type 1 Diabetes
NCT03565666 · Massachusetts General Hospital
2018-07-09 – 2018-11-19 · Type1 Diabetes Mellitus
What this study did
Phase 2 (1)
Type 1 Diabetes
NCT03816761 · Novo Nordisk A/S
2019-02-25 – 2019-06-10 · Diabetes Mellitus, Type 1
What this study did
Phase 1 (22)
Type 1 Diabetes
NCT03723759 · Novo Nordisk A/S
2018-10-26 – 2019-03-27 · Diabetes Mellitus, Type 1
What this study did
NCT03407599 · Novo Nordisk A/S
2018-01-08 – 2018-07-05 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT02568280 · Novo Nordisk A/S
2015-10-06 – 2016-04-25 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT02003677 · Novo Nordisk A/S
2013-11-29 – 2014-08-14 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT02035371 · Novo Nordisk A/S
2014-01-13 – 2014-07-24 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT02131246 · Novo Nordisk A/S
2014-05 – 2014-07 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT02033239 · Novo Nordisk A/S
2014-01 – 2014-06 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01934712 · Novo Nordisk A/S
2013-08-30 – 2014-01-28 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01924637 · Novo Nordisk A/S
2013-08 – 2013-11 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01682902 · Novo Nordisk A/S
2012-09 – 2013-03 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01618188 · Novo Nordisk A/S
2012-06-11 – 2012-09-07 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01469143 · Novo Nordisk A/S
2011-11 – 2012-01 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01121289 · Novo Nordisk A/S
2010-04 – 2010-07 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT04698018 · Novo Nordisk A/S
2021-04-20 – 2022-07-22 · Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
What this study did
NCT02933853 · Novo Nordisk A/S
2016-10-14 – 2017-12-21 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01121276 · Novo Nordisk A/S
2010-04 – 2010-09 · Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT05184868 · Arecor Limited
2022-01-03 – 2022-09-09 · Diabetes Mellitus, Type 1
What this study did
NCT03959514 · Arecor Limited
2019-04-12 – 2019-08-08 · Diabetes Mellitus, Type 1
What this study did
NCT01296438 · Novo Nordisk A/S
2011-02 – 2011-03 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Phase 4 (6)
Type 1 Diabetes
NCT04772729 · Medical University of Warsaw
2021-03-01 – 2024-03-01 · Diabetes type1, Diabetes Mellitus, Type 1
What this study did
NCT03659799 · Institut de Recherches Cliniques de Montreal
2019-04-12 – 2023-03-30 · Type 1 Diabetes Mellitus
What this study did
NCT04620967 · Kirsten Nørgaard
2021-02-01 – 2022-06-30 · Type 1 Diabetes
What this study did
NCT04414579 · Mountain Diabetes and Endocrine Center
2019-03-27 – 2021-03 · Type 1 Diabetes Mellitus
What this study did
Other / comorbidity
NCT04381429 · University Hospital, Strasbourg, France
2020-08-17 – 2025-01-20 · Cystic Fibrosis-related Diabetes
What this study did
NCT03554486 · Stanford University
2018-07-23 – 2019-03-30 · Diabetes Mellitus, Type 1
What this study did
Early phase / not applicable (9)
Type 1 Diabetes
NCT05224258 · Medtronic MiniMed, Inc.
2022-03-17 – 2024-06-21 · Type 1 Diabetes
What this study did
NCT04759144 · University of Cambridge
2021-03-12 – 2022-12-01 · Type 1 Diabetes Mellitus
What this study did
NCT04163874 · McGill University
2020-02-14 – 2022-01-30 · Type 1 Diabetes, Type 1 Diabetes Mellitus, Hyperglycemia, Postprandial
What this study did
NCT04200313 · Jaeb Center for Health Research
2020-03-31 – 2022-01-14 · Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT04853030 · University of Ljubljana, Faculty of Medicine
2021-04-06 – 2021-09-20 · Type 1 Diabetes
What this study did
NCT03993366 · McGill University
2019-03-01 – 2019-08-06 · Type 1 Diabetes Mellitus
What this study did
NCT03212950 · University of Ljubljana, Faculty of Medicine
2017-07-10 – 2017-11-01 · Type 1 Diabetes Mellitus
What this study did
Type 2 Diabetes
NCT07652528 · Hallym University
2026-08 – 2028-12 · Sudden Sensorineural Hearing Loss (SSNHL), Prediabetes / Type 2 Diabetes
What this study did
Other / comorbidity
NCT03579615 · Manchester University NHS Foundation Trust
2020-12-23 – 2022-08-01 · Diabetes Mellitus, Type 1
What this study did
Used as active comparator (4)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 1 (3)
Type 1 Diabetes
NCT05262595 · Novo Nordisk A/S
2022-03-03 – 2022-09-05 · Diabetes Mellitus, Type 1
What this study did
NCT04655690 · Novo Nordisk A/S
2020-11-09 – 2021-11-26 · Diabetes Mellitus, Type 1
What this study did
Early phase / not applicable (1)
Type 1 Diabetes
NCT05199714 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2022-02-21 – 2023-03-25 · Type 1 Diabetes
What this study did

Competitive landscape

This mechanism is crowded: 8 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Type 1 Diabetes: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Insulin Aspart (Fiasp): this drugApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
AfrezzaApprovedPeptideInsulinPartial signal
NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed
NCT01445951: Change in HbA1c from baseline to week 24 (LS mean): Technosphere Insulin (Gen2 inhaler) plus basal insulin -0.21% vs insulin aspart plus basal insulin -0.40%; difference 0.19% (95% CI 0.02 to 0.36), inside the pre-specified non-inferiority margin of 0.4% (CT.gov posted analysis).
Insulin Aspart (NovoLog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Degludec (Tresiba)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Detemir (Levemir)
ApprovedUS marketing discontinued
PeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Lantus)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Basaglar)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Toujeo)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glulisine (Apidra)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin HumanApproved—Insulinnot yet gradedNo reviewed efficacy summary in this indication
Insulin Lispro (Humalog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Lispro (Lyumjev)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin NPH (Humulin N)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Pramlintide (Symlin)
ApprovedUS marketing discontinued
PeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
CadisegliatinPhase 3Small moleculeGlucokinasenot yet gradedNo reviewed efficacy summary in this indication
Sotagliflozin (Inpefa)Phase 3Small moleculeSGLT1/2 (dual)not yet gradedNo reviewed efficacy summary in this indication
ZimislecelPhase 3Cell therapyPancreatic islet cells (VX-880 is a stem cell-derived therapy, not a small molecule drug), Pancreatic islet cell replacementnot yet gradedNo reviewed efficacy summary in this indication
IcovamenibPhase 2Small moleculeMeninnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Insulin aspart (Fiasp) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
June 2028 (1)
Early phase / not applicableType 2 DiabetesNot yet recruiting
Est. primary completion 2028-06 · NCT07652528 · CT.gov ↗
What to watch

See the full readout calendar ↗